02065nas a2200349   4500000000100000008004100001260001300042653001500055653001000070653002600080653002400106653001000130653001100140653001600151653001100167653002100178653001200199653002500211653000900236653002500245653002100270100001700291700001500308700001500323700001400338245013700352856004100489300001000530490000700540520115400547022001401701       1990                            d  c1990 Mar10aAdolescent10aAdult10aAntibodies, Bacterial10aAntigens, Bacterial10aChild10aFemale10aGlycolipids10aHumans10aImmunoglobulin M10aleprosy10aLongitudinal studies10aMale10aMycobacterium leprae10aPapua New Guinea1 aBagshawe A F1 aGarsia R J1 aBaumgart K1 aAstbury L00aIgM serum antibodies to phenolic glycolipid-I and clinical leprosy: two years' observation in a community with hyperendemic leprosy.  uhttp://ila.ilsl.br/pdfs/v58n1a04.pdf  a25-300 v583 a<p>A village population with hyperendemic leprosy in Papua New Guinea was repeatedly examined for clinical leprosy and for serum IgM antibodies to phenolic glycolipid-I (APGL-I) over 2 years between 1984 and 1986. In 1984, serum APGL-I was elevated in 15% of the subjects without clinical leprosy, and the prevalence of seropositivity was not significantly different in subjects from households with or without leprosy. In 1986, the prevalence of elevated serum APGL-I in leprosy-free subjects had risen to 23%. The incidence of seroconversion from APGL-I negative to APGL-I positive was 9.5% per year (95/1000 person years) in 253 subjects tested in 1984 and 1986. During the same period, 27 of 40 (67%) leprosy-free subjects reverted from positive to negative. The positive seroconversion rate in the community was higher than the incidence of clinical leprosy (11.2/1000 person years) over the same period. However, elevated serum APGL-I was not associated with clinical disease and failed to predict the development of disease over 2 years. The significance of persistent seropositivity found in 14 (5%) leprosy-free subjects is uncertain.</p>
  a0148-916X